Protalix Biotherapeutics Inc
AMEX:PLX
Intrinsic Value
The intrinsic value of one PLX stock under the Base Case scenario is 11.13 USD. Compared to the current market price of 1.54 USD, Protalix Biotherapeutics Inc is Undervalued by 86%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation History
Protalix Biotherapeutics Inc
Loading...
Fundamental Analysis

Revenue & Expenses Breakdown
Protalix Biotherapeutics Inc
Balance Sheet Decomposition
Protalix Biotherapeutics Inc
Current Assets | 60.5m |
Cash & Short-Term Investments | 19.5m |
Receivables | 4.7m |
Other Current Assets | 36.4m |
Non-Current Assets | 13.4m |
PP&E | 10m |
Other Non-Current Assets | 3.4m |
Free Cash Flow Analysis
Protalix Biotherapeutics Inc
USD | |
Free Cash Flow | USD |
Earnings Waterfall
Protalix Biotherapeutics Inc
Revenue
|
59.8m
USD
|
Cost of Revenue
|
-29.9m
USD
|
Gross Profit
|
29.9m
USD
|
Operating Expenses
|
-25.2m
USD
|
Operating Income
|
4.6m
USD
|
Other Expenses
|
-720k
USD
|
Net Income
|
3.9m
USD
|
PLX Profitability Score
Profitability Due Diligence
Protalix Biotherapeutics Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
Score
Protalix Biotherapeutics Inc's profitability score is 51/100. The higher the profitability score, the more profitable the company is.
PLX Solvency Score
Solvency Due Diligence
Protalix Biotherapeutics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Score
Protalix Biotherapeutics Inc's solvency score is 49/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
PLX Price Targets Summary
Protalix Biotherapeutics Inc
Dividends
Current shareholder yield for PLX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
The intrinsic value of one PLX stock under the Base Case scenario is 11.13 USD.
Compared to the current market price of 1.54 USD, Protalix Biotherapeutics Inc is Undervalued by 86%.